Personalized nutrition and epigenetics: Biohax's Tailored Script tests the push for clinical proof

The nutrition market is moving beyond the traditional distinction between general dietary guidance and supplements designed to address specific needs. The growing availability of biological tests, digital tools and analytical services has fueled interest in an approach in which nutritional recommendations are tailored to individual characteristics.

The idea behind personalized nutrition is that people do not all respond to foods and nutritional interventions in the same way. Age, genetics, metabolism, the microbiome, lifestyle and physiological conditions can all contribute to differences in individual needs and responses.

However, the market faces a fundamental challenge: not every biological difference can automatically be translated into a useful recommendation. For personalization to have clinical and commercial value, it is necessary to demonstrate that the data collected are reliable, that their interpretation is scientifically sound and that the interventions produce measurable results.

The Limitations of a Market Built on Standardized Formulas

The supplement industry offers a wide range of products targeting different objectives, from general nutritional support to the management of specific deficiencies. Many consumers, however, choose products based on habits, marketing information or guidance that is not always linked to an individual assessment.

The result can be an overlap of products, ingredients and dosages, without it always being clear which are actually necessary or what benefits consumers can reasonably expect.

This does not mean that standardized supplements are ineffective. They can play an appropriate role when specific nutritional requirements or documented deficiencies are present. The problem arises when a formula is presented as a universal solution to needs that may differ from one person to another.

Personalized nutrition seeks to address this gap by using individual information to guide choices. Its commercial potential lies in the ability to offer more relevant services that can be updated over time, while the challenge is to demonstrate that the additional cost of personalization is justified by the results.

What Can Epigenetics Tell Us?

Epigenetics studies the mechanisms through which gene activity is regulated without altering the DNA sequence itself. One of the most extensively studied processes is DNA methylation, a chemical modification that can influence gene expression and varies in response to biological and environmental factors.

Diet, physical activity, environmental exposures, aging and other factors can be associated with changes in methylation patterns. For this reason, epigenetics is attracting growing interest in research on biomarkers, biological aging and potential applications in precision nutrition.

A scientific review published in 2025 in Nature Reviews Genetics explored the role of epigenetic variability in individual differences, highlighting the complex relationship between genetic makeup, the environment and the regulation of gene expression.

This complexity calls for caution when interpreting test results. A biomarker can provide useful information about specific biological processes without necessarily being able to diagnose a disease, accurately predict an individual's risk or determine which supplement would be most appropriate.

The distinction between association and causation is fundamental. The fact that an epigenetic pattern is associated with a particular condition does not, on its own, demonstrate that changing it through diet will produce a clinical benefit.

From Biological Measurement to Nutritional Recommendations

Developing a personalized nutrition service requires connecting several stages: data collection, biomarker analysis, scientific interpretation and the definition of an intervention.

Each step introduces potential sources of error. Results depend on sample quality, laboratory methodology, measurement reproducibility and the validity of the algorithms used to interpret the data.

Furthermore, biomarkers are not all equivalent. Some are well established for specific clinical applications, while others are still being researched and require further verification before they can support healthcare decisions.

A systematic review published in 2024 in Frontiers in Aging examined clinical studies on nutritional strategies that could influence DNA methylation and epigenetic clocks. The paper highlights the scientific interest of this field, but also the need for more robust studies to assess the effectiveness of these interventions.

For businesses, the implications are tangible: developing a sophisticated test is not enough. Companies must demonstrate that the results can be meaningfully interpreted and that the recommendations derived from them offer an advantage over conventional nutritional approaches.

Personalization may also require periodic updates. If biological conditions change, a system may provide for new measurements and adjustments to the intervention. This creates opportunities for recurring-service business models, but also increases requirements in terms of quality control, data management and communication of results.

A Promising Market with Significant Responsibilities

Personalized nutrition sits at the intersection of wellness, technology and biomedical research. For businesses, it can open up new revenue streams through testing, consultations, individualized formulations and digital services.

However, the commercialization of solutions that use biological data requires particular care. Information must be handled in compliance with privacy requirements, and marketing claims must reflect the actual level of scientific evidence available.

The personalization of supplements also involves technical and regulatory constraints. Combining numerous ingredients into a single formulation requires checks on compatibility, safety, dosages and potential interactions. The ability to create an individualized formula does not eliminate the need for controls and professional supervision.

The value of this model will therefore depend on the ability to integrate innovation, reliable production, clinical evidence and an experience that consumers can easily understand.

Biohax and the Attempt to Connect Epigenetics with Nutrition

Biohax, a US startup developing an epigenetics-based personalized nutrition platform, operates in this context. According to its profile on UCapital Dealflow, the system uses DNA methylation patterns derived from a blood sample collected at home to generate proprietary biological indicators, which the company calls Epigenetic Biomarker Proxies.

The Tailored Script® platform aims to combine multiple ingredients into a personalized daily formulation, with potential updates based on subsequent measurements. The company also states that its initial commercial strategy focuses on clinical partners and B2B channels, before a possible broader expansion.

The profile reports a seed fundraising target of $10 million. This information describes the project and the company's stated strategy, but does not in itself constitute independent validation of the system's clinical effectiveness.

Assessing the development of this model will require examining the quality of the evidence supporting its biomarkers, the reproducibility of its analyses, the results of any clinical studies and its ability to convert partnerships into sustainable revenue.

This is precisely the central issue for the entire sector: personalized nutrition can become a significant market when the collection of biological data translates into genuinely useful decisions. The challenge is not simply to make nutrition more individualized, but to demonstrate that personalization improves outcomes without amplifying costs, complexity and expectations unsupported by scientific evidence.

Biohax — "Epigenetics-Driven Personalized Nutrition Platform"